EBS Emergent BioSolutions Inc.

Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day

Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day

-  Organizations Join Together to Raise Awareness of Overdose Reversal Medicines During August 31st Games

GAITHERSBURG, Md., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it is teaming up with the Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and Mothers Against Prescription Drug Abuse (MAPDA) to highlight the importance of potentially lifesaving overdose reversal medicines on International Overdose Awareness Day 2020. International Overdose Awareness Day is a global event held on August 31 each year that aims to raise awareness of overdose and reduce the stigma of drug-related deaths. Emergent, in collaboration with these teams and MAPDA, will address the importance of accessing overdose reversal medicines through special announcements, videos, and stadium presentations.

“Emergent is committed to doing everything we can to increase awareness, access, and availability of potentially lifesaving overdose reversal medicines,” said Doug White, SVP and devices business unit head at Emergent BioSolutions. “We are proud to team up with the Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA on International Overdose Awareness Day to highlight the important role that overdose reversal medicines play in preparing individuals and families in the event of an accidental opioid overdose. Everyone can take a stand and take action by talking to their doctor or pharmacists about having immediate access to overdose reversal medicines.”

“By increasing awareness about the importance of having immediate access to overdose reversal medicines, we may empower individuals to be prepared in the event of an opioid overdose emergency,” said Mary Bono, former U.S. Congresswoman and chairman and CEO of MAPDA. “MAPDA is honored to stand alongside Emergent, the Boston Red Sox, Cincinnati Reds, and Philadelphia Phillies, to help more individuals know about and access potentially lifesaving medicines to treat opioid overdoses.”

For more information, visit: .

About Emergent BioSolutions

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030.

About MAPDA

Mothers Against Prescription Drug Abuse (MAPDA) is a nonprofit consumer organization started by three mothers who lost children to prescription drug overdoses. The organization aims to prevent prescription drug abuse before it starts and support individuals in recovery. Mary Bono, a well-known political speaker and consumer advocate, now heads up the organization headquartered in the Washington DC suburbs. Learn more at MAPDA.net.

Media Contact:

Miko B. Neri

Senior Director, Global Communications & Public Affairs

240-631-3392

 

Investor Contact:

Robert G. Burrows

Vice President, Investor Relations

240-631-3280

  

EN
31/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE

Emergent BioSolutions Supports Voices for Awareness and Facing Fentany...

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™ GAITHERSBURG, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- As opioid emergencies continue to be the leading cause of accidental death in the United States,1 Emergent BioSolutions (NYSE: EBS) is teaming up with Voices for Awareness and Facing Fentanyl Now in honor of National Fentanyl Prevention and Awareness Day™ on August 21, 2025. As part of this year’s efforts, these leading advocacy organizations and its sponsors will bring their message to Times...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Emergent BioSolutions Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 14 August 2025 in which we reassessed the appropriateness of the ratings in the ...

 PRESS RELEASE

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

Emergent BioSolutions Reports Second Quarter 2025 Financial Results Second Quarter 2025 Total Revenues of $140.9 million, above Q2 guidance by $21 millionSecond Quarter 2025 Net Loss of $12.0 million and Net Loss Margin of (9)%, an improvement of 96% and 10,200 bps, respectively, versus prior yearSecond Quarter 2025 Gross Margin % of 36% and Adjusted Gross Margin % of 49%, an expansion of 6,200 bps and 2,300 bps, respectively, versus prior yearSecond Quarter 2025 Adjusted EBITDA of $28.5 million, an increase of 382% versus prior yearSecond Quarter 2025 Adjusted EBITDA Margin of 20% of Total...

 PRESS RELEASE

New Publication in Expert Review of Anti-infective Therapy Evaluates B...

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovation GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the publication of a comprehensive review article, "Brincidofovir in the Era of Mpox," in the peer-reviewed journal Expert Review of Anti-infective Therapy.1 This publication includes an overview of brincidofovir, in vitro and in v...

 PRESS RELEASE

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. Ho...

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announces its recognition of the U.S. House of Representatives for adding over-the-counter (OTC) naloxone to every AED location in its buildings, providing direct access to first responders and anyone coming across an individual who may be experiencing an opioid overdose. This effort has been led by Representative Buddy Carter (R-GA), with his team and congressional constituents, who have kept this pu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch